“In relationship to the Hansoh GLP-1, we said that moving to clinic this year and everything is on schedule.”

In context

“date would be really important. I do think that many of the KOLs have been waiting to see the data from HYPERION because it gives them a sense of prescribing it earlier in their journey, so they'll be very interested in that. There is a patient population in PAH, for example, who are overlapped with connective tissue diseases. And they're going to want to see the culmination of all that data across the 3 trials, and that data individually and that data pooled will be very important. And clearly, clearly, the continued SOTERIA and the fact that the adverse effects and all of this sort of thing are well within the label are things that are going to create an interest of the KOLs to begin to adopt this earlier in the journey and to other patient populations such as connective tissue disease. In relationship to the Hansoh GLP-1, we said that moving to clinic this year and everything is on schedule. Operator: Our next question comes from Terence Flynn with Morgan Stanley. Terence C. Flynn: I was just -- I was wondering if you could offer any preliminary perspective on how a 15% tariff on pharmaceuticals would impact your 2026 outlook. Recognize you're not going to give guidance at this point, but I was just wondering if you could help frame for us the potential impact there. And then any insight if this would be phased in over time or if this would be implemented more near term? Robert M. Davis: Yes. Terence, this is Rob. I appreciate the question. Maybe I'll take the second part of it first. So we need to see more clarity both from the administration and just overall as to exactly how this is going to play out. So it's still not clear exactly how this relates relative to the 232 inv”